China keeps delivering new assets and studies, now in HER2+ gastric 🇨🇳
KC-WISE updated OS at #ESMO26. Double-blind phase 3 in HER2+ GC/GEJC after progression on trastuzumab: anbenitamab (biparatopic HER2 bispecific) + chemo vs placebo + chemo.
• ORR 56 vs 14% • mPFS 7.1 vs 2.7 mo • mOS 19.6 vs 9.7 mo, HR
Almost 20 months median OS in second line. The control arm is single-agent chemo, so the bar wasn't high. But the OS doubled, and that's hard to argue with.
Takeaway: HER2 is still a target after trastuzumab. Sequential HER2 blockade works.
The question I can't answer yet: HERIZON just moved zanidatamab to 1L. Once patients get a biparatopic up front, does a second one still work in 2L? Or does that spot go to T-DXd?
Also, Should point out 20 months is significantly lower than what we saw on HERIZON which hit 26-27 month.
@OncoAlert @TheGutOncLab
869 views · 16 likes · 9 reposts · 0 replies
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.orgSafety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study
https://esmocongress.esmo.orgA global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide
https://esmocongress.esmo.orgComparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching
https://esmocongress.esmo.orgPatient-reported outcomes (PROs) from DESTINY-Breast05: Health-related quality of life (HRQoL) with trastuzumab Deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (Pts) with high-risk HER2-positive early breast cancer (eBC)
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgSource: Nicholas Hornstein · x.com